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Abstract
Background: Abnormal clot structure has been identified in patients with thrombotic 
disorders. Anticoagulant therapy offers clear benefits for thrombosis prevention and 
treatment by reducing blood clot formation and size; nevertheless, there are limited 
data on the effects of different anticoagulants, where clotting is initiated with differ-
ent triggers, on clot structure.
Objectives: Our aim was to investigate the effects of vitamin K antagonists and fac-
tor Xa inhibitors on clot structure.
Methods: Clots from pooled plasma spiked with rivaroxaban, apixaban, or enoxapa-
rin, as well as plasma from patients on warfarin, were compared to plasma without 
anticoagulation. The kinetic profile of polymerizing clots was obtained by turbidity, 
fiber density was determined by confocal microscopy, clot pore size was investigated 
by permeation, and fiber size was analyzed using scanning electron microscopy. 
Clotting agonist was either tissue factor or thrombin.
Results: Following clotting with tissue factor, all anticoagulated clots had a signifi-
cantly increased lag time, with the exception of enoxaparin. Rivaroxaban addition-
ally led to significantly less dense and more permeable clots, with thicker fibers. In 
contrast, turbidity analysis following initiation with thrombin showed few effects of 
anticoagulation, with only enoxaparin leading to a prolonged lag time. Enoxaparin 
clots made with thrombin were less dense and more permeable.
Conclusion: Our results show that anticoagulants modulate clot structure particu-
larly when induced by tissue factor, most likely due to reduction of thrombin gen-
eration. We propose that the effects of different anticoagulants could be assessed 
with a global clot structure measurement such as permeation or turbidity, providing 
information on clot phenotype.
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Essentials
• Anticoagulant therapies are associated with different bleeding risks.
• There are limited data on the effects of anticoagulants on fibrin clot structure.
• Initiation with tissue factor but not thrombin reveals effects of direct oral anticoagulants on clot structure.
• Clot structure could be used as a global test for anticoagulant activity.
1  | INTRODUCTION
Thrombosis is a major contributor to global disease burden, being 
a serious and lethal component of cardiovascular diseases such as 
ischemic heart disease, stroke, and venous thromboembolism.1,2 
Thromboembolic conditions accounted for one in four deaths 
worldwide in 2010 and remain the leading cause of death around 
the world.3-6 Anticoagulants decrease blood clot formation by tar-
geting and modulating the coagulation pathway and are, therefore, 
commonly administered to prevent and treat thromboembolic disor-
ders.7 However, all anticoagulant drugs to date are associated with 
a certain bleeding risk that needs to be considered in the decision of 
anticoagulation administration.8,9
Conventionally, individuals with thrombosis received a com-
bination of low-molecular-weight heparins (LMWHs), followed by 
vitamin K antagonists (VKAs), particularly warfarin. Direct oral an-
ticoagulants (DOACs), which directly inhibit thrombin or activated 
factor X (FXa), have more recently been developed. Unlike warfarin, 
DOACs can be administered at fixed doses, thus reducing the num-
ber of hospital visits for drug monitoring.10,11
Previous studies have shown that fibrin clot structure is abnor-
mal in individuals with thrombotic conditions, and individuals with 
with postthrombotic syndrome and recurrent venous thromboem-
bolism (VTE) patients have denser clots with thinner fibers that are 
resistant to fibrinolysis.12 In addition, clots from individuals with 
deep vein thrombosis were also shown to be thinner, less porous, 
and more resistant to lysis.13 These studies indicate that abnormal 
fibrin clot structure is associated with patients with thrombotic dis-
orders. Anticoagulants, including warfarin and DOACs, have been 
shown to alter fibrin clot structure by increasing clot porosity and 
altering clot density.11,14,15 Direct thrombin inhibitors have also been 
shown to delay thrombin generation and increase clot permeabil-
ity.16,17 In addition, anticoagulants have been shown to delay clotting 
lag time and increase the efficiency of clot lysis.11,18-21
The effects of anticoagulants on clot structure have been 
previously investigated using thrombin12,13,15,22 or tissue factor 
(TF),11,14,16,17,19-21,23,24 as well as TF-bearing cells25,26 as clotting ago-
nists. In addition, thrombus growth and fibrin distribution patterns, 
related to clot stability, have also been studied with TF-bearing col-
lagen surfaces.27,28 TF has been reported to better reflect effects of 
VKAs on clot density and permeability.29 In this study, we compared 
clot structure in plasma from individuals on warfarin, pooled plasma 
(PP) spiked with the direct FXa inhibitors rivaroxaban and apixaban, 
and PP spiked with the indirect FXa inhibitor enoxaparin, to PP con-
trol using a range of sensitive methods that analyze clot density, 
porosity, and fiber thickness. We thus used a comprehensive set 
of clot structure analysis methods to directly compare the effects 
of VKAs and indirect/direct FXa inhibitors on fibrin clot structure 
when clotting was triggered with either thrombin or TF.
2  | MATERIALS AND METHODS
2.1 | Materials
Alexa Fluor 594–fibrinogen (Thermo Fisher Scientific, Altrincham, 
UK) was reconstituted in double-distilled water (ddH2O) to 2.5 mg/
mL. Human thrombin (Merck Diagnostics, Darmstadt, Germany) was 
reconstituted to 250 U/mL in ddH2O and stored at –80°C. Dilutions 
were performed in 0.05M Tris-Base, 0.1 M NaCl, pH 7.4 (TBS). PPP-
Reagent (Stago, Parsippany, NJ, USA) was reconstituted in 1 mL of 
ddH2O to 30 pM of TF and 24 µM phospholipids. All other chemicals 
were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless stated 
otherwise.
Apixaban and rivaroxaban powder (MedChemExpress, Princeton, 
NJ, USA) were initially reconstituted in dimethyl sulfoxide and sub-
sequently diluted 1:9 in deionized water. They were spiked in nor-
mal-pooled plasma (NPP) at concentrations of apixaban 128 ng/mL 
and rivaroxaban 174 ng/mL both at therapeutic levels. Enoxaparin 
sodium (Clexane) was spiked in NPP at concentration 0.35 U/mL, 
that is, equivalent to a prophylactic dose.
2.2 | Blood collection
A pool of plasma from 355 outpatient clinic (preoperative assess-
ment) patients with normal international normalized ratio (INR)/
activated partial thromboplastin time was obtained from an-
onymized normal citrated samples (Vacuette, Greiner Bio-One, 
Monroe, NC USA) and analyzed in the Coagulation Laboratory 
at Mater Dei Hospital (Msida, Malta). As our pooled plasma was 
obtained from individuals undergoing a wide range of surgical 
procedures, it includes a mixture of individuals with and with-
out underlying health conditions. All samples underwent double 
centrifugation (10 minutes at 2500 g twice, using the Eppendorf 
Centrifuge 5810, Eppendorf AG, Germany) to obtain platelet-poor 
plasma (PPP), and they were frozen at −80°C. They were subse-
quently spiked with apixaban, rivaroxaban, and enoxaparin at the 
desired concentrations. Warfarinized PPP was collected from an-
onymized outpatients’ samples receiving warfarin therapy. There 
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were two pools of warfarinized plasma, that is, INR 2.2 (samples 
of patients with INR 2-3) and INR 4.1 (samples from patients with 
INR 4-6) to represent therapeutic and supratherapeutic INR, re-
spectively. They were prepared following the same protocol of 
the plasma spiked with anticoagulants and underwent an identi-
cal number of freeze-thaw cycles. Frozen anticoagulated samples 
were shipped to Leeds and Sheffield on dry ice. Pooled plasma 
(PP) with a measured fibrinogen concentration of 4.64 mg/mL 
was used as reference. PP from individuals on warfarin INR 2.2 
(3.80 mg/mL fibrinogen) and plasma from individuals on warfarin 
INR 4.1 (4.31 mg/mL fibrinogen) were chosen, as their fibrinogen 
levels were most similar to PP.
The prothrombin time/INR assay, fibrinogen concentrations, and 
the anti-Xa assay for enoxaparin were performed using an ACL TOP 
500 analyzer (Instrumentation Laboratory, Bedford, MA, USA) and 
the following reagents: HemosIL RecombiPlasTin 2G, HemosIL QFA 
Thrombin (Bovine), and HemosIL Liquid Anti-Xa kit (Instrumentation 
Laboratory). The anti-Xa assays for apixaban and rivaroxaban were 
performed in the Coagulation Laboratory at the Royal Hallamshire 
Hospital, using the analyser Sysmex CS-5100 (Siemens Healthcare 
Diagnostics Products GmbH, Marburg, Germany) and the Biophen 
DiXal kit (Hyphen BioMed, Neuville-sur-Oise, France) with specific 
calibrators.
Finally, normal pooled platelet-poor plasma (NPP) used in some 
of the supplementary experiments was obtained from 30 healthy 
individuals at the Leeds Institute of Cardiovascular and Metabolic 
Medicine, with a fibrinogen concentration of 3.4 mg/mL.
2.3 | Thromboelastography
Thromboelastography (TEG) was performed at Mater Dei Hospital 
(Msida, Malta) on citrated PPP, using a TEG5000 (Thromboelastograph 
Hemostasis Analyser, Haemoscope, Haemonetics Corporation, 
Braintree, MA, USA) with dedicated software (TEG Analytical 
Software version 4.2.3, Haemoscope, Haemonetics Corporation).
The native TEG used citrated PPP 330 µl and CaCl2 0.2M 30 µl 
(without the addition of a clotting trigger such as thrombin or TF) 
and was performed in duplicate, using the two channels provided. 
The results were expressed as mean ± SD.
2.4 | Turbidity analysis of polymerizing fibrin clots
The kinetic profile of polymerizing fibrin clots was investigated by 
turbidity, using a standardized protocol as previously described.30 In 
brief, plasma was diluted to a final ratio of 1 in 6 in TBS and loaded 
onto 384-well plates (Thermo Fisher Scientific, Altrincham, UK) in 
triplicates. An activation mixture of 5 mM CaCl2 (final concentration) 
and either tissue factor (final concentration, 1 pM) or thrombin (final 
concentration, 0.1 U/mL) was added to initiate clotting. Thrombin 
concentration was chosen following optimization for this and other 
methods described. TF concentration used in all methods was chosen 
to reflect the low TF concentration used in the calibrated automated 
thrombogram thrombin generation assay. Changes in absorbance 
(or optical density) were measured at 340 nm every 17 seconds for 
1 hour at 37°C using a Powerwave microtiter-plate reader (Bio-Tek, 
Swindon, UK). The parameters analyzed from the turbidity profile 
were lag time to initiation of polymerization, maximum absorbance 
(an indicator of fiber diameter) and average rate of clotting (based 
on the rate between 25% and 75% clotting). Turbidity experiments 
were performed in duplicate or triplicate, each with three technical 
replicates.
2.5 | Laser scanning confocal microscopy
Plasma was diluted to a final ratio of 1 in 6 with TBS and spiked with 
Alexa Fluor 594 labeled fibrinogen at 50 µg/mL final concentration. 
Clotting was triggered by the addition of 5 mM CaCl2 (final concen-
tration) and either TF (final concentration, 1 pM) or thrombin (final 
concentration, 0.1 U/mL). Once clotting was initiated, the mixture 
was immediately transferred to the channel of an uncoated µ-Slide 
VI 0.4 mm (Ibidi GmbH, Gräfelfing, Germany), and placed in a dark 
humidity chamber for 2 hours at room temperature to allow clots to 
form. Images were obtained using a Zeiss LSM880 inverted micro-
scope with a 40× oil immersion lens. Optical z-stacks (43 × 0.7 µm) 
were combined and flattened to show maximum intensity. Fiber den-
sity was determined by averaging the total number of fibers crossing 
an arbitrary straight line of fixed length (200 µm). Image processing 
and fiber counting were executed on ImageJ software. Fibrin clots 
were prepared in triplicate, and three density measurements were 
obtained per clot.
2.6 | Clot permeation
The clot permeability assay was adapted from a previously described 
method.31 Plasma samples were diluted to a final ratio of 1 in 8.8 
with TBS. Clotting was initiated by the addition of an activation 
mixture containing 10 mM CaCl2 (final concentration) and either TF 
(final concentration 1 pM) or thrombin (final concentration, 0.5 U/
mL). Immediately after initiation of clotting, the mixture was trans-
ferred to the channel of an Ibidi uncoated µ-Slide VI 0.4 mm, then 
placed in a humidity chamber for 1 hour at room temperature to 
allow clots to form. A plastic syringe was connected to the well cor-
responding to the channel holding the clot, and a constant pressure 
was applied by filling the syringe with TBS to a set height (4 cm). 
The clots were washed in this manner for 30 minutes, and flow rates 
of buffer through the clots were then measured, by collecting and 
weighing the buffer flow-through, every 10 minutes for 40 minutes. 
Volume (correlated to weight, assuming 1g = 1mL) of flow-through 
over time was plotted and fitted by linear regression (R2 ≥ 0.99). 
The permeation coefficient (Ks, Darcy constant) was calculated as 
previously described.32 The slightly higher plasma dilution factor, 
thrombin, and calcium concentrations were required to obtain a 
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measurable flow rate in the permeation assay. Permeation experi-
ments were performed in triplicate or quadruplicate.
2.7 | Scanning electron microscopy
Clots for scanning electron microscopy (SEM) were prepared and 
imaged using a previously described method.33 In brief, plasma was 
diluted 1 in 6 with TBS, and clotting was triggered by the addition 
of an activation mixture consisting of 10 mM CaCl2 (final concen-
tration) and either TF (final concentration, 1 pM) or thrombin (final 
concentration, 1 U/mL). Immediately following clotting initiation, the 
mixture was transferred to pierced Eppendorf lids and placed in a 
humidity chamber for 2 hours to allow for clot formation. Clots were 
washed 3 times for 40 minutes with saline solution and fixed in 2% 
glutaraldehyde overnight. Once fixed, clots were washed 3 times for 
40 minutes with sodium cacodylate buffer (50 mM C2H12AsNaO5, 
pH 7.4) and dehydrated in increasing concentrations of acetone 
(30%-100%). Clots underwent critical point drying with CO2 before 
being mounted onto stubs and sputter coated with 10 nm of iridium 
using a Cressington 208 HR (Cressington Scientific Instruments, 
Watford, UK). Each clot was formed in triplicate and imaged in three 
different areas at different magnifications, 5000-40 000×) using a 
Hitachi SU8230 high-performance cold field emission SEM (Chiyoda 
Corporation, Yokohoma, Japan). Fibrin fiber thickness was analyzed 
on images at 20 000× using ImageJ.
2.8 | Statistical Analysis
Data are presented as mean of at least three replicates ± SE, un-
less otherwise stated. Differences between groups was determined 
by one-way analysis of variance or Kruskal–Wallis test, following 
Shapiro–Wilk test for normality, followed by Tukey–Kramer post 
hoc test or Dunn–Bonferroni to determine significant differences 
to control group. Data analysis was performed using OriginPro 




Clot formation in the absence of a clotting trigger was analysed 
by native TEG (Table 1). The average R time, reflective of the lag 
time before the start of clotting, was increased for PP spiked with 
the direct FXa inhibitor rivaroxaban (19.55 ± 0.07 minutes; P < .05) 
and enoxaparin (23.35 ± 0.35 minutes; P < .05), compared to con-
trol (12.97 ± 3.26 minutes). Clot formation time (K time) was also 
increased for PP spiked with direct FXa inhibitors (rivaroxaban, 
7.50 ± 2.12 minutes; and apixaban, 6.00 ± 3.11 minutes; P < .05) 
and enoxaparin (11.40 ± 2.12 min; P < .05), compared to con-
trol (2.64 ± 0.55 minutes). The α-angle corresponding to the tan-
gent line angle from 2 mm to 20 mm amplitude was narrower for 
PP spiked with rivaroxaban (27.40 ± 7.92°; P < .05) and enoxaparin 
(17.40 ± 0.99°; P < .05), compared to control (52.2 ± 7.6°). We also 
observed a slight increase in maximum amplitude (MA), reflective 
of the ultimate clot strength, for both warfarinized plasma samples 
(INR, 2.2 37.80 ± 2.83 mm; INR, 4.1 38.05 ± 1.34 mm; P < .05) and 
a small reduction for PP spiked with rivaroxaban (28.40 ± 0.57 mm; 
P < .05) and enoxaparin (28.20 ± 0.99 mm; P < .05) relative to control 
(32.92 ± 1.86 mm).
3.2 | Clotting initiation with TF
Turbidity analysis of clots formed with TF showed clear differences 
in polymerization (Figure 1A). For instance, the lag time was signifi-
cantly (P < .0001) longer for warfarinized plasma samples (2-fold 
R time (min) K time (min) α-angle (deg) MA (mm)
PP 12.97 ± 3.26 2.64 ± 0.55 52.47 ± 7.65 32.92 ± 1.86
Warfarinized PP
INR 2.2
10.85 ± 1.34 2.80 ± 1.41 54.10 ± 15.84 37.80 ± 2.83*
Warfarinized PP
INR 4.1
16.25 ± 6.01 3.75 ± 1.34 41.85 ± 10.82 38.05 ± 1.34*
PP + rivaroxaban
(174 ng/mL)
19.55 ± 0.07* 7.50 ± 2.12* 27.40 ± 7.92* 28.40 ± 0.57*
PP + apixaban
(128 ng/mL)
15.65 ± 4.45 6.00 ± 3.11* 36.95 ± 17.89 33.40 ± 6.65
PP + enoxaparin
(0.35 U/mL)
23.35 ± 0.35* 11.40 ± 2.12* 17.40 ± 0.99* 28.20 ± 0.99*
Note: ±SD.
Abbreviations: INR, international normalized ratio; MA, maximum amplitude; PP, pooled platelet-
poor plasma; TEG, thromboelastography.
*P < .05 (Mann-Whitney nonparametric U test for the comparison with PP). 
TA B L E  1   TEG results of analysis of 
recalcified plasma samples containing 
different anticoagulants, in the absence of 
clotting triggers
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and 2.9-fold for INR 2.2 and 4.1, respectively), and plasma spiked 
with rivaroxaban (2.3-fold) and apixaban (1.8-fold). The delay in clot 
formation for these samples suggests impaired protofibril formation 
and are in agreement with the longer K time obtained for FXa in-
hibitors in native TEG (Table 1). No change in lag time was observed 
for plasma spiked with enoxaparin (Figure 1B). Furthermore, there 
were no changes in maximum absorbance (MaxOD) for plasma sam-
ples containing anticoagulants compared to control (Figure 1C). 
Warfarinized plasma at INR 4.1 did, however, show a slower rate of 
clotting (3.5-fold; P < .05) (Figure 1D). A slower average rate indi-
cates that longer time was required for clots to achieve 75% clot-
ting from 25%, where MaxOD equates to 100% clot formation. Time 
to 50% clotting and time to maximum rate of clotting (Vmax) follow 
the same pattern observed for lag time for these samples (Figure 
S1). A batch of (NPP from healthy individuals was spiked with higher 
concentrations of enoxaparin, equivalent to therapeutic dosage. Lag 
time for NPP + 0.6 U/mL enoxaparin was over 20 minutes, with nei-
ther NPP + 1 U/mL nor NPP + 2 U/mL clotting in 1 hour (Figure S2A).
3.3 | Clotting initiation with thrombin
Turbidity analysis of polymerizing clots, when clotting was initiated 
with thrombin, showed relatively comparable curve patterns for plasma 
samples containing anticoagulants compared to control (Figure 2A). 
Interestingly, lag time was 3-fold longer (P < .0001) for plasma samples 
spiked with enoxaparin compared to control (Figure 2B), suggesting 
impaired protofibril formation. Although LMWHs have reduced abil-
ity to inhibit thrombin due to their smaller size,34 the observed longer 
lag time for plasma containing enoxaparin after addition of thrombin 
clearly shows that this anticoagulant still has an effect on thrombin ac-
tivity. This observation is also in agreement with the changes observed 
F I G U R E  1   Turbidity analysis parameters of polymerizing clots with tissue factor. Clotting of diluted plasma samples was initiated 
with tissue factor and parameters of warfarinized plasma with international normalized ratio 2.2 (War2.2) and 4.1 (War4.1), and pooled 
plasma (PP) spiked with rivaroxaban (Rivarox.), apixaban (Apix.) or enoxaparin (Enox.) were compared against PP control. Turbidity curve of 
polymerizing clots; (A), error bars correspond to ± SE of two replicates, with three technical replicates. From turbidity curves clotting lag 
time (B), maximum absorbance (MaxOD) of fully polymerized clots (C), and average rate of clotting, defined by changes in absorbance over 
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by native TEG for the enoxaparin clot (Table 1). Similarly to results dis-
cussed above where clots were formed with tissue factor, there were 
no changes in MaxOD for clots formed with thrombin (Figure 2C). 
Nevertheless, the average rate of clotting was 2.6-fold (P < .0001) 
slower for warfarinized plasma at INR 4.1 (Figure 2D). Time to 50% 
clotting and Vmax followed the same pattern observed for average rate 
of clotting and lag time for these samples (Figure S3). NPP spiked with 
0.6-2 U/mL enoxaparin produced no detectable clots (Figure S4).
3.4 | Fiber density and permeability following 
clotting initiation with TF
The structural architecture of fully formed clots, resulting from 
clotting initiation with tissue factor, was investigated using laser 
scanning confocal microscopy. There was a visual decrease in fiber 
density for warfarinized plasma at INR 4.1 and plasma contain-
ing rivaroxaban and apixaban (Figure 3C, D, and E, respectively) 
in comparison to control (Figure 3A). Moreover, average fiber 
number per 200 µm was decreased for these samples in rela-
tion to PP (89 ± 7), namely, warfarin INR 4.1 (78 ± 11, P < .05), 
rivaroxaban (71 ± 4, P < .0001), and apixaban (78 ± 7, P < .01) 
(Figure 3G). Correspondingly, the permeation coefficient (Ks) was 
increased for clots of PP (1.8 ± 0.6 × 10−8 cm2) spiked with rivar-
oxaban (3.7 ± 0.3 × 10−8 cm2, P < .01) and apixaban (3.0 ± 0.2 × 10-
8 cm2, P < .05), indicating larger clot pore size for these samples 
(Figure 3H). Three-by-three tile scans show mostly homogeneity of 
the structure of clots (Figure S5). The decrease in fiber density and 
increase in porosity observed for rivaroxaban clots are in agree-
ment with the decreased MA observed for rivaroxaban clots by 
F I G U R E  2   Turbidity analysis parameters of polymerizing clots with thrombin. Clotting of diluted plasma samples was initiated with 
thrombin and parameters of warfarinized plasma with international normalized ratio 2.2 (War2.2) and 4.1 (War4.1), and pooled plasma (PP) 
spiked with rivaroxaban (Rivarox.), apixaban (Apix.) or enoxaparin (Enox.) were compared against PP control. Turbidity curve of polymerizing 
clots; graph is a representation of one of four repeats (A), error bars correspond to ± SE of three technical replicates. From turbidity curves 
clotting lag time (B), maximum absorbance (MaxOD) of fully polymerized clots (C), and average rate of clotting, defined by changes in 
absorbance over time (D), were determined. Each data point represents the average of three technical replicates. Error bars correspond 
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native TEG (Table 1). Clots from plasma containing higher concen-
trations of enoxaparin, namely, 0.6 U/mL (7.3 ± 0.1 × 10-8 cm2) and 
1 U/mL (8.0 ± 0.2 × 10−8 cm2) also had increased (P < .05) pore size 
compared to control (3.7 ± 0.5 × 10−8 cm2) (Figure S2B). A higher 
Ks value was also observed for NPP containing 2 U/mL of enoxa-
parin (11.0 × 10−8 cm2; Figure S2B); however, only a single value 
was obtained as clots from further repeats did not withstand the 
constant flow. Confocal images of clots containing 0.6 U/mL enoxa-
parin confirmed a looser structure and decreased fiber number per 
200 µm (36 ± 10) when compared to control (93 ± 2; P < .0001; 
Figure S2C), with higher concentrations of enoxaparin producing 
no visible clots.
F I G U R E  3   Fibrin fiber density and porosity of fully formed clots following clotting with tissue factor. Confocal microscopy images of 
pooled plasma (PP) (A), warfarin international normalized ratio (INR) 2.2 (B), warfarin INR 4.1 (C), PP + rivaroxaban (D), PP + apixaban (E), and 
PP + enoxaparin (F) were used to calculate fibrin fiber density (G). Images are a representation of one of three repeats, each imaged in three 
different areas of the clot. Each data point corresponds to individual measurements of three replicates. Scale bar represents 50 μm. Fibrin 
clot porosity (H) was determined by the permeation coefficient (Ks), where higher Ks values indicate a more porous fibrin fiber network, and 
lower Ks values suggest a less porous fibrin fiber network. Each data point corresponds to one of three replicates. Error bars correspond 
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3.5 | Fiber density and permeability following 
clotting initiation with thrombin
Fully formed clots produced with thrombin were also studied by 
laser scanning microscopy. Clots of warfarinized plasma (Figure 4B 
and C) were visually denser than control (Figure 4A). In addition, 
plasma spiked with enoxaparin formed visually less dense clots 
(Figure 4F). These visual observations correlated to the average fiber 
number in 200 µm, where warfarinized plasma samples, INR 2.2 
(75 ± 2; P < .01) and INR 4.1 (77 ± 9; P < .05), had a higher average 
fiber count than PP (64 ± 6) and enoxaparin-spiked plasma (45 ± 15; 
P < .01) (Figure 4G). Again, 3 × 3 tile scans showed homogeneity 
F I G U R E  4   Fibrin fiber density and porosity of fully formed clots following clotting with thrombin. Confocal microscopy images of pooled 
plasma (PP) (A), warfarin international normalized ratio (INR) 2.2 (B), warfarin INR 4.1 (C), PP + rivaroxaban (D), PP + apixaban (E), and 
PP + enoxaparin (F) were used to calculate fibrin fiber density (G). Images are a representation of one of three repeats, each imaged in three 
different areas of the clot. Each data point corresponds to individual measurements of three replicates. Scale bar represents 50 μm. Fibrin 
clot porosity (H) was determined by the permeation coefficient (Ks), where higher Ks values indicate a more porous fibrin fiber network, 
and lower Ks values suggest a less porous fibrin fiber network. Each data point corresponds to one of five replicates. Error bars correspond 
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of all clots, excluding enoxaparin clots, which present a heteroge-
neous fibrin distribution (Figure S6). The fiber density follows the 
same trend as the MA results obtained by native TEG (Table 1). 
Moreover, clots of plasma containing enoxaparin had increased Ks 
(5.6 ± 0.9 × 10−8 cm2; P < .01) when thrombin was used as a trig-
ger, correlating to larger pore size in these clots compared to control 
(3.5 ± 0.9 × 10−8 cm2) (Figure 4H). Permeation data and confocal im-
ages could not be obtained for NPP spiked with 0.6-2 U/mL enoxa-
parin, as no clots were formed at these concentrations.
3.6 | Fiber size following clotting initiation with 
TF or thrombin
Finally, we used SEM to analyze fibrin fiber diameters. SEM images of 
fully formed clots, where TF was used as the clotting trigger, showed 
visually less dense clots formed with warfarinized plasma INR 4.1 
and plasma spiked with rivaroxaban and apixaban, when compared 
to control (Figure 5A-F). These observations corroborate the fiber 
density data obtained from laser confocal microscopy images, de-
scribed above (Figure 3G). Moreover, SEM images from clots formed 
following clotting with thrombin also showed the same pattern 
determined by the average fiber counts of the corresponding sam-
ples (Figure 4G). Namely, clots from warfarinized plasma appeared 
denser, while clots from plasma spiked with enoxaparin were looser 
(Figure 5G-L). Clots of plasma spiked with rivaroxaban, formed with 
TF, had increased fiber diameter size (108 ± 10 nm; P < .01) when 
compared to control (93 ± 9 nm) (Figure 5M). Increased fiber size for 
rivaroxaban clots correlated to their reduced density, observed by 
confocal microscopy (Figure 3G). Furthermore, warfarinized plasma 
produced clots with decreased fiber size following clotting initiation 
with thrombin (INR 2.2, 83 ± 3 nm; P < .05; and INR 4.1, 85 ± 9; 
P < .05) relative to control (88 ± 5 nm) (Figure 5N). This observation 
also correlated with the increased clot density for both warfarinized 
plasma samples, described above (Figure 4G).
4  | DISCUSSION
Our study provides a novel systematic and comprehensive direct 
comparison of alterations on fibrin clot structure, caused by differ-
ent classes of anticoagulants, detected with an array of different 
sensitive methods. In agreement with previous studies on changes in 
clot structure by VKAs,29 we find that the effects of anticoagulants 
on clot structure is highly dependent on the agonist used to initiate 
clotting. The mode of action of each anticoagulant used in this study 
is highlighted in a coagulation cascade schematic in the supplemen-
tary data (Figure S7). A summary of the observed changes in clot 
structure parameters following clotting with either TF or thrombin 
is shown in Table 2.
Triggering clotting with TF or thrombin distinctly impacted on 
the structure of clots formed with warfarinized plasma samples and 
plasma containing direct FXa inhibitors or LMWH. Most striking is 
the fact that the most significant changes in clot structure observed 
with TF were seen in the rivaroxaban clots, which showed no signif-
icant changes when thrombin was used. Similarly, clotting activation 
with thrombin showed the most significant changes in enoxaparin 
clots, whereas no significant changes were observed with TF. We 
hypothesize that the effects observed for enoxaparin clots with 
thrombin (increased lag time, decreased density, and increased po-
rosity) are directly attributable to the direct effects of this drug on 
thrombin, via interaction with antithrombin.34 Indeed, the effects 
of thrombin concentration on clot structure, with reduced throm-
bin concentrations generating less dense clots with larger pores, are 
well known and likely explain these findings.25,35 TF-bearing cells 
have also been shown to regulate the rate of fibrin formation from 
the cell surface through thrombin generation, modulating the sta-
bility and three-dimensional structure of the clot.26,36 In addition, 
elevated prothrombin concentrations have been shown to decrease 
fiber mass-to-length ratio and alter thrombin generation, when clot-
ting initiated by TF-bearing cells.25 No changes in clot structure for 
the FXa inhibitors were seen with thrombin, most likely due to the 
fact that their mode of action is upstream and largely bypassed by 
the exogenously added thrombin. Conversely, TF activation is up-
stream of factor X, allowing FXa inhibitors to demonstrate clear 
effects on clotting activity and clot structure. A previous study re-
porting less dense clots produced by endothelial cells following in-
hibition of TF activity further demonstrates the active role of TF on 
impacting clot structure.37 We conclude from this study that clotting 
initiation with TF provides more accurate depictions of the effects 
of DOACs and VKA on clot structure, corroborating previous re-
ports. Effects of LMWH on clot structure, however, are sensitively 
detected with thrombin. Interestingly, native TEG results showed 
the most significant changes for both rivaroxaban and enoxaparin 
clots. In the absence of a trigger, and in the presence of calcium, 
the intrinsic pathway eventually leads to thrombin generation and 
clot formation. This alternative clot formation pathway to the ones 
targeted by the other triggers used in this study, supports the TEG 
findings and places further emphasis on the importance of clotting 
trigger selection when investigating clot structure.
Dosages of anticoagulants were chosen to reflect treatment 
levels, with the exception of enoxaparin for which the prophylactic 
dose was chosen due to the fact that therapeutic concentrations of 
enoxaparin (equivalent to 0.5-1.0 anti-FXa U/mL bidaily or 1.0-2.0 
anti-FXa U/mL once daily)38 had such potent effects on clot struc-
ture as to impair analysis (Supplementary Table S1). We also ob-
served that clot structure was influenced by different levels of VKA. 
This study suggests that clot structure analysis techniques, such as 
permeation and turbidity, have the potential to be used to assess the 
effects of anticoagulation drugs on patient clot phenotype.
Apparent discrepancies in data obtained by different method-
ologies may be attributed to the physical state of the clot, namely, 
hydrated fully polymerized clots (confocal and permeation), pro-
cessed fully polymerized clots (SEM) and hydrated polymerizing 
clots (turbidity). From this, we conclude that data obtained from 
the different methodologies used to investigate clot structure 
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are mostly complementary, with different structural properties 
such as permeability and fiber thickness being measured by each 
method. Our study has a number of limitations. The potential clin-
ical application of these finding will need to be further assessed in 
future clinical studies using patient samples. A second limitation 
of this study was that confocal and SEM analyses were not per-
formed in a blinded manner to eliminate any potential unconscious 
bias. A third limitation is the use of a PP spiked with anticoagulants 
rather than patient plasma, as patients requiring anticoagulation 
have a prothrombotic clot phenotype that is not reflective of the 
“normal” clot phenotype. A future comparison between pre- and 
post-anticoagulation in patient plasma would provide further 
assessment of impact different anticoagulants have on clot pa-
rameters relevant to clinical practice, and whether anticoagulant 
treatment is able to revert a prothrombotic clot phenotype to a 
normal clot phenotype. Nevertheless, the PP used as a control in 
this study was obtained from a large number of individuals before 
they underwent a range of surgical procedures. It therefore in-
cludes individuals with and without underlying health conditions, 
which indicates that this PP is not entirely normal, as also indi-
cated by a slightly above normal average fibrinogen concentration. 
Future studies with patient plasma would help to identify the best 
global clot structure method, for instance, permeation or turbid-
ity, which do not require specialist equipment and provide quan-
titative data in just a few hours, with the potential to become a 
screening test for changes in clot structure.
Further limitations of the study include the use of a single con-
centration of clotting agonists and DOACs. In vivo, the concentra-
tion of free thrombin changes over the course of clot formation 
and thrombin concentration has been shown to directly influence 
clot structure, including fiber thickness and clot density.25,26,35,36 
Future studies correlating thrombin generation and clot structure 
would add value to the findings of this study. In addition, future 
investigations into the effect of different DOAC concentrations 
on alleviating prothrombotic clot phenotype could help determine 
a dosage to effect threshold for these drugs. Another limitation 
of the study was the fact that, due to warfarin’s mode of action, 
this could not be spiked into the same control PP as the other an-
ticoagulants and was instead obtained from individuals treated 
with warfarin. We recognize that the PP from the two groups of 
patients on warfarin may have different properties than the PP 
used as a control. However, by matching the samples’ fibrinogen 
concentration, which is known to influence clot structure as well 
as feasibly possible, we ensured that the best possible comparison 
could be achieved.
In summary, we have shown that clot structure is significantly 
altered by different anticoagulants using an array of techniques and 
direct in vitro comparisons. In agreement with previous reports, our 
data show that the choice of trigger for clotting is important when 
investigating clot structure in samples containing different types of 
anticoagulants, with TF providing the most sensitive and accurate 
comparisons for the DOACs used in this study. Further studies are 
required to establish how these methods may contribute to a cor-
relation of clot structure with clinical data either at the start of anti-
coagulation or over the course of treatment. Identifying changes in 
clot phenotype using clot structure measurements, such as perme-
ation and turbidity, could ultimately help in the prevention of bleed-
ing as well as thrombotic events.
F I G U R E  5   Fibrin fiber size and scanning electron microscopy (SEM) images of fully formed clots following clotting with tissue factor or 
thrombin. SEM images of pooled plasma (PP) (A), warfarin international normalized ratio (INR) 2.2 (B), warfarin INR 4.1 (C), PP + rivaroxaban 
(D), PP + apixaban (E), and PP + enoxaparin (F) clots following clotting initiation with tissue factor. SEM images of PP (G), warfarin INR 2.2 
(H), warfarin INR 4.1 (I), PP + rivaroxaban (J), PP + apixaban (K), and PP + enoxaparin (L) clots following clotting initiation with thrombin. 
Images are a representation of one of three repeats. Scale bar represents 5 μm. Fiber size was measured from SEM images, each imaged in 
three different areas of the clot, at 10 000x magnification following clotting activation by tissue factor (M) and thrombin (N). Each data point 
corresponds to individual measurements of three replicates. Error bars correspond to ± SE. *P < .05, **P < .01
TA B L E  2   Summary of changes in clot structure parameters following clotting with tissue factor or thrombin
Tissue factor Thrombin
War. 2.2 War. 4.1 Rivarox. Apix. Enox. War. 2.2 War. 4.1 Rivarox. Apix. Enox.
MaxOD - - - - - - - - - -
Lag time ↑ ↑ ↑ ↑ - - - - - ↑
Av. Rate ↓ ↓ - - - - ↓ - - -
Fiber density - ↓ ↓ ↓ - ↑ ↑ ↓
Pore size - - ↑ ↑ - - - - - ↑
Fiber size - - ↑ - - ↓ ↓ - - -
Note: - no significant change; ↑ significant increase, P ≤ .05; ↓ significant decrease, P ≤ .05.
Abbreviation: MaxOD, maximum absorbance.
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